/Resmed%20Inc_%20meds-by%20Steven%20Lee%20via%20iStock.jpg)
ResMed Inc. (RMD), headquartered in San Diego, California, manufactures, distributes, and markets medical devices and cloud-based software applications. Valued at $35.7 billion by market cap, the company offers a range of products for respiratory disorders, including diagnostic tools like ApneaLink Air and NightOwl, cloud-based platforms like AirView and myAir for patient monitoring, and U-Sleep for HME providers, connectivity solutions, as well as out-of-hospital software solutions. The sleep tech giant is expected to announce its fiscal second-quarter earnings for 2026 in the near future.
Ahead of the event, analysts expect RMD to report a profit of $2.68 per share on a diluted basis, up 10.3% from $2.43 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.